Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 - New Market Report


Print article Print article
2013-12-08 16:28:17 - Recently published research from GlobalData, "MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022", is now available at Fast Market Research

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

MnB rLP2086 is Pfizer's recombinant protein vaccine that protects against MenB disease. Despite Pfizer's position as a major player in the vaccine industry, MnB rLP2086 is currently the only meningococcal vaccine in the pharmaceutical giant's portfolio. Originally developed by Wyeth, Pfizer acquired MnB rLP2086 with its purchase of the company in 2009. MnB rLP2086 is a bivalent vaccine composed of two variants of the N. meningitidis OMP LP2086, A05, and B01. LP086 is a lipoprotein (LP) linked to the outer membrane

of the bacteria and promotes in vivo survival by binding Factor H and facilitating complement evasion.

Scope

* Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on MnB rLP2086 including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for MnB rLP2086 for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Full Report Details at
- www.fastmr.com/prod/719825_mnb_rlp2086_meningococcal_vaccines_fo ..

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of MnB rLP2086 performance
* Obtain sales forecast for MnB rLP2086 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Meningococcal Immunization Policy
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 MnB rLP2086
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 Dosing and Formulation
6.5 Potential Clinical Positioning
6.6 Potential Commercial Positioning
6.7 Pricing and Reimbursement
6.8 SWOT Analysis
6.9 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Vaccine Coverage
7.4.2 Vaccine Approval vs. Routine Schedule Inclusion
7.4.3 Vaccines Included
7.4.4 Key Launch Dates
7.4.5 General Pricing Assumptions
7.4.6 Individual Vaccine Assumptions
7.5 Physicians and Specialists Included in this Study
7.6 About the Authors
7.6.1 Authors
7.6.2 Reviewers
7.6.3 Global Head of Healthcare
7.7 About GlobalData
7.8 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of Meningococcal Disease
Table 2: Meningococcal Immunization Recommendation Agencies by Country
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012
Table 4: Leading Vaccines for Meningococcal Disease, 2012
Table 5: Product Profile - MnB rLP2086
Table 6: MnB rLP2086 SWOT Analysis, 2012
Table 7: Global Sales Forecasts ($m) for MnB rLP2086, 2012-2022
Table 8: Key Launch Dates
Table 9: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: Membrane Structure of N. meningitidis

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com